NYSE:CRL

Charles River Laboratories Announces First-Quarter 2024 Results

Retrieved on: 
Thursday, May 9, 2024
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, Sale, FDA, Safety, Investment, Annual report, Security (finance), Justice, Conference, Research, Organic, USDA, Risk, Bank, Acquisition, Perception, NHP, Government, Drug discovery, GAAP

Charles River has scheduled a live webcast on Thursday, May 9th, at 8:30 a.m.

Key Points: 
  • Charles River has scheduled a live webcast on Thursday, May 9th, at 8:30 a.m.
  • Charles River will present at the Bank of America 2024 Healthcare Conference in Las Vegas, Nevada, on Wednesday, May 15th, at 10:00 a.m. PT (1:00pm ET).
  • Non-GAAP results also allow investors to compare the Company’s operations against the financial results of other companies in the industry who similarly provide non-GAAP results.
  • Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this press release except as required by law.

CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories’ Directors and Officers for Breach of Fiduciary Duties

Retrieved on: 
Tuesday, April 23, 2024
CRL, LLP, Primate, Exchange, SAN

SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to CRL and its shareholders.

Key Points: 
  • SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to CRL and its shareholders.
  • If you are a current Charles River shareholder, you may have legal claims that may be brought on behalf of the company, against CRL’s directors and officers.
  • In February 2023, Charles River was informed by the Department of Justice that in conjunction with the U.S.
  • Johnson Fistel LLP’s investigation seeks to determine whether Charles River’s senior officers or members of its board of directors harmed the company by breaching their fiduciary duties or otherwise violating securities laws in connection with the foregoing alleged conduct.

Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP

Retrieved on: 
Thursday, May 2, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Medical Devices, Genetics, Consistency, Gold standard, Roadmap, Doctor of Philosophy, Cell, AAV, Quality, CGT, CDMO, Booth, Discovery, Patient, Gene, Society, Good manufacturing practice, CRL, LVV, GMP, Annual general meeting, Final product, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality.
  • Moving towards a gold standard for reference materials, Charles River is introducing six AAV reference material serotypes, offering superior empty and full capsid ratios and high vector genome concentration (GC/mL), plus five LVV reference material products, available with different combinations of promoters and reporter genes.
  • Charles River will officially launch its AAV and LVV reference materials with supporting case study data during the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, May 7 – 11, 2024, in Baltimore, MD.
  • We look forward to showcasing our robust portfolio and supporting data during the ASGCT Annual Meeting.” – Ramin Baghirzade, PhD, Senior Director, Global Head Commercial, Gene Therapy CDMO Services, Charles River

Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally

Retrieved on: 
Monday, April 22, 2024
Environmental, Social and Governance (ESG), Alternative Energy, Green Technology, Energy, Climate Change, Sustainability, Socially Responsible Investing, Pharmaceutical, General Health, Professional Services, Medical Devices, Environment, Biotechnology, Science, Research, Health, RE100, Privacy law, Schneider Electric, Heat, Partnership, Electricity, Urban Saints, Repsol, Earth Day, GHG, Multimedia, CRL, Organization, Renewable resource, Corporate social responsibility, Renewable energy

In 2020, Charles River became one of the first 300 members of RE100 , a global corporate renewable energy initiative, and committed to operating on 100 percent renewable electricity globally by 2030.

Key Points: 
  • In 2020, Charles River became one of the first 300 members of RE100 , a global corporate renewable energy initiative, and committed to operating on 100 percent renewable electricity globally by 2030.
  • View the full release here: https://www.businesswire.com/news/home/20240422679591/en/
    In efforts to reach its renewable electricity target, Charles River has:
    Executed two critical virtual power purchase agreements (vPPAs) in the United States and Europe.
  • In 2022, Charles River was recognized by the U.S. Environmental Protection Agency’s Green Power Partnership as a leader in green electricity use.
  • Charles River also sponsored Energize , a program powered by Schneider Electric to increase access to renewable energy for pharmaceutical supply chains.

Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing

Retrieved on: 
Tuesday, April 16, 2024
Research, Animal Welfare, Medical Devices, Public Policy, Government, Biotechnology, Health, Pharmaceutical, General Health, Science, Corporation, Safety, Policy, Valo, AI, Animal, Pathology, Logica, Patient safety, AMAP, Patient, The three Rs, Multimedia, Non-governmental organization, Drug development, CRL, Drug discovery, Pharmaceutical industry

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing.
  • This investment spans a portfolio of technology innovations, partnerships, and advocacy efforts to reduce the use of animal testing.
  • View the full release here: https://www.businesswire.com/news/home/20240416134140/en/
    Understanding that stakeholders across drug development must collaborate to pursue these advances, AMAP is comprised of Charles River experts in animal welfare, science, technology, operations, and advocacy.
  • AMAP focus is on three key pillars:
    Products & Services: Charles River is committed to innovating and expanding its portfolio to include more animal alternatives.

Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call

Retrieved on: 
Friday, April 12, 2024
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, CRL

Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens.
  • A conference call has been scheduled to discuss this information on Thursday, May 9th, at 8:30 a.m.
  • Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com .
  • A replay will be accessible through the same website.

Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology

Retrieved on: 
Thursday, April 11, 2024
Data Management, Biotechnology, Technology, Health, General Health, Pharmaceutical, Medical Devices, Research, Software, Artificial Intelligence, Science, Safety, Tissue, Doctor of Philosophy, Pathology, Marie Cassidy, Charles River Laboratories, MBA, Drug development, CRL, Drug discovery, WSI, Organization

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology AI.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology AI.
  • In experimental and toxicologic pathology in particular, traditional light microscopic pathology methods can fall short of maintaining consistency and efficiency in analyzing histopathology data.
  • By augmenting evaluations with decision support technology, toxicologic pathologists have access to simple, visual tools to facilitate efficiency, consistency, and accuracy in their work.
  • Developed through a research collaboration between Charles River and Deciphex, Patholytix Foresight incorporates organ-based lesion classifiers created from an extensive data warehouse.

CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, April 3, 2024
Risk, Telephone, Primate, Defendant, Complaint, CRL, Research, P.C

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Charles River Laboratories International, Inc. (NYSE: CRL) on behalf of long-term stockholders following a class action complaint that was filed against Charles River on May 19, 2023 with a Class Period from May 5, 2020 to February 21, 2023.

Key Points: 
  • NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Charles River Laboratories International, Inc. (NYSE: CRL) on behalf of long-term stockholders following a class action complaint that was filed against Charles River on May 19, 2023 with a Class Period from May 5, 2020 to February 21, 2023.
  • Our investigation concerns whether the board of directors of Charles River have breached their fiduciary duties to the company.
  • According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.
  • There is no cost or obligation to you.

Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics

Retrieved on: 
Tuesday, April 9, 2024
Research, Medical Devices, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Deafness, CDMO, Obesity, Syndrome, Infertility, Entrepreneurship, Disease, Diabetes, Ciliopathy, Patient, CRL, DNA, Display resolution, Kidney disease, GMP, Tecmar, Therapy, Paratriathlon, BBS, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd .

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd .
  • Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.
  • Dysfunctional cilia can cause blindness, deafness, chronic respiratory infections, kidney disease, heart disease, infertility, obesity and diabetes.
  • In recent years, Charles River has significantly broadened its cell and gene therapy portfolio to simplify complex supply chains and meet the growing demand for plasmid DNA, viral vector, and cell therapy services.

Charles River to Perform Plasmid Production for Ship of Theseus

Retrieved on: 
Thursday, April 4, 2024
Research, Medical Devices, Genetics, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Diabetes, Neutropenia, CDMO, Psoriasis, Infertility, Cancer, MCB, Tissue, CRL, DNA, Pattern hair loss, HOX, Ship, Acquisition, Factorization of polynomials, Display resolution, GMP, Good manufacturing practice, Tecmar, Therapy, HQ, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.
  • Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate.
  • Charles River’s GMP plasmid DNA CDMO center of excellence based in Keele, United Kingdom will lead the collaboration, providing services that include plasmid DNA backbone generation, plasmid synthesis, GMP master cell bank (MCB) generation, pre-production evaluation, and GMP plasmid DNA manufacture including in-house release testing.
  • We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to bringing our therapies to patients.” – Jeremy Elser, Founding CEO, Ship of Theseus